CYP2G1P

Across TCGA pan-cancer cohorts, CYP2G1P mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CYP2G1P data layer compared with 17 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CYP2G1P mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CYP2G1P expression acts as an unfavorable survival marker.

HNSC, COAD, and PDAC are the cancer types where CYP2G1P mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Quartile	III,IV	0.581	0.912	.002	15	view →
COAD	DFS	Median	All	0.806	1.000	.043	12	view →
PDAC	DFS	Tertile	II,III,IV	0.703	0.742	.022	4	view →
LUAD	OS	Median	All	0.960	1.000	.019	3	view →
LSCC	OS	Median	II,III,IV	0.647	0.882	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CYP2G1P–HNSC (OS)

Open the HNSC breakdown →